Physician profile
Anna Perez
NPI 1902503584
$793.39
in general payments reported to CMS, 2019-2025
10 companies · $793 in 2025
The $793 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $793.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $793.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $271.47 | 2025 | Rezdiffra |
| Ardelyx, INC. | $126.27 | 2025 | Ibsrela |
| Globus Medical, INC. | $121.02 | 2025 | Senza |
| Lemaitre Vascular, INC. | $87.96 | 2025 | Artegraft Vascular Graft, Restoreflow, Hydro Lemaitre Valvulotome |
| Boston Scientific Corporation | $46.56 | 2025 | General - Therapies |
| Abiomed | $37.10 | 2025 | |
| Exact Sciences Corporation | $35.91 | 2025 | The Cologuard Plus Collection Kit |
| Axsome Therapeutics, INC. | $33.20 | 2025 | Symbravo |
| Lilly USA, LLC | $19.83 | 2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $14.07 | 2025 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.